A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
Clinical trial NCT05815485 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05815485
- Sponsor
- The University of Texas Medical Branch, Galveston
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-04
- Primary completion
- 2026-04-01
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.